Oakland, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Institute For Evolvable Medicines, founded in 2024, is a small nonprofit in the Human Services sector that reported $909K in total revenue in fiscal year 2025. The organization ran a surplus of $315K, a strong 35% operating margin.
The specific purpose of this corporation is to research and develop a completely new class of 'evolvable' medicines
The Institute for Evolvable Medicines develops next-generation therapeutics designed to adapt and evolve within the body to combat rapidly mutating diseases, including cancer, viruses, and...
The Institute for Evolvable Medicines develops next-generation therapeutics designed to adapt and evolve within the body to combat rapidly mutating diseases, including cancer, viruses, and antibiotic-resistant bacteria. The organizations work focuses on advancing biologically based medicines through preclinical research, manufacturing, and regulatory preparation toward human clinical trials.Patients with life-threatening diseases; research activities conducted in the United States.In 2025, the organization advanced its lead therapeutic candidate, EM0924, through preclinical development. Activities included manufacturing process development, analytical development, nonclinical testing, and preparation for regulatory submission of an Investigational New Drug (IND) application.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2025 | 2024 | Change | |
|---|---|---|---|
| Revenue | $908,805 | N/A | N/A |
| Expenses | $594,228 | N/A | N/A |
| Net Income | $314,577 | N/A | N/A |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Leor Weinberger | CEO | 8.00 |
Officer
Director
|
$151,921 | $0 | $151,921 |
| Galyn Susman | Secretary-CFO | 8.00 |
Officer
Director
|
$88,461 | $0 | $88,461 |
| Brian Kaye | Treasurer | 1.00 |
Director
|
$0 | $0 | $0 |
| Nancy Halgwood | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Stuart Tyner | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| David J Bacon | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Wendy Sammons-Jackson | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $908,805 | $594,228 | $1,377,529 | $314,577 |
Compare Institute For Evolvable Medicines with other nonprofits in California and across the country.